Statute Details
- Title: Health Products (Active Ingredients) Regulations 2023
- Act Code: HPA2007-S831-2023
- Type: Subsidiary Legislation (SL)
- Enacting Authority: Health Sciences Authority (HSA) with Minister for Health’s approval
- Authorising Act: Health Products Act 2007 (sections 47 and 72)
- Commencement: 18 December 2023
- Current Version: Current version as at 27 March 2026
- Parts: Part 1 (Preliminary); Part 2 (Prohibition); Part 3 (Licences); Part 4 (Duties); Part 5 (Certificates); Part 6 (Miscellaneous); Schedule (Regulated active ingredients)
- Key Definitions (examples): “appropriate non-proprietary name”, “Good Manufacturing Practice standard”, “Good Distribution Practice standard”, “manufacture”, “psychotropic substance”, “qualified pharmacist”
- Key Sections (high level): s 4–5 (prohibitions); ss 6–11 (licence requirements); ss 15–21 (storage/transport/import/export/supply duties); ss 22–25 (records and recall notification); ss 31–34 (export/manufacturing/distribution certificates); ss 35–37 (enforcement and procedural matters)
What Is This Legislation About?
The Health Products (Active Ingredients) Regulations 2023 (“Active Ingredients Regulations”) form a regulatory framework under Singapore’s Health Products Act 2007 for the handling of “active ingredients” that are listed in the Schedule. In plain terms, the Regulations aim to prevent unsafe, ineffective, or unlawful health products from entering the supply chain by controlling who may manufacture, import, and wholesale regulated active ingredients, and by imposing compliance duties on those who do.
The Regulations are particularly concerned with the risks posed by adulterated, counterfeit, or otherwise unwholesome active ingredients. They prohibit certain conduct (including manufacture and import/supply of such ingredients), require licences for key stages of the supply chain, and mandate operational controls—such as proper storage and transport, documentation, and recall-related recordkeeping. They also create a certification regime for active ingredients intended for export, supporting traceability and quality assurance beyond Singapore’s borders.
Practically, the Regulations are designed for businesses and professionals involved in the lifecycle of regulated active ingredients: manufacturers, importers, wholesalers, and (in limited contexts) other persons who may be exempt from licensing. The Regulations also interact with broader Singapore health-product regulation, including licensing of retail pharmacies and rules for clinical research materials, medical devices, and therapeutic products (notably for “psychotropic substances”).
What Are the Key Provisions?
1) Prohibitions against dealing with unsafe or unlawful active ingredients (Part 2). The Regulations establish core compliance boundaries. Section 4 prohibits the manufacture of adulterated, counterfeit, or unwholesome active ingredients. Section 5 prohibits the import or supply of adulterated, counterfeit, etc., active ingredients. While the extract provided does not reproduce the full statutory definitions of “adulterated”, “counterfeit”, or “unwholesome”, the structure makes clear that the Regulations target both quality defects (adulteration/unwholesomeness) and integrity failures (counterfeiting). For practitioners, this means that even if a party holds a licence, it must still ensure that the active ingredient itself meets the required standards and is not misrepresented or contaminated.
2) Licensing regime for manufacture, import, and wholesale (Part 3). The Regulations require licences for the principal commercial activities involving regulated active ingredients. Section 6 requires a manufacturer’s licence for manufacture. Section 7 requires an importer’s licence for import. Section 8 requires a wholesaler’s licence for wholesale. Sections 9–11 provide categories of persons who do not require manufacturer’s, importer’s, or wholesaler’s licences, respectively. These exemptions are critical for advising clients: the question is not only whether an activity occurs, but whether it falls within an exempt category (for example, certain limited activities, or activities performed by persons already regulated under other licensing regimes).
3) Requirements for issue of licences (Division 2 of Part 3). Sections 12–14 set out the requirements for issuing manufacturer’s, importer’s, and wholesaler’s licences. Although the extract does not include the full text, the Regulations’ defined terms indicate that licence issuance is likely tied to compliance with recognised quality and distribution standards. The Regulations define “Good Manufacturing Practice standard” by reference to the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme Guide to Good Manufacturing Practice for Medicinal Products, and define “Good Distribution Practice standard” by reference to HSA guidance notes and other approved standards. In practice, counsel should expect that applicants must demonstrate capability to meet these standards, including systems for quality control, supplier oversight, and distribution integrity.
4) Operational duties: storage, transport, import/export, and supply (Part 4). Part 4 imposes detailed duties on persons dealing with active ingredients. Division 1 covers storage and transport. Section 15 requires proper storage of active ingredients, and Section 16 governs transport. These provisions are typically aimed at preventing degradation, contamination, mix-ups, or loss of traceability. Division 2 addresses import/export and supply. Sections 17 and 18 deal specifically with import/export of active ingredients that are “psychotropic substances” (as defined by reference to the First Schedule to the Health Products (Therapeutic Products) Regulations 2016). This signals that psychotropic substances are subject to heightened controls, likely including additional documentation, authorisation, or handling constraints.
Section 19 provides that there is no retail supply of active ingredients. This is a significant commercial constraint: it channels active ingredients through licensed wholesale and manufacturing pathways rather than direct retail sale. Section 20 requires that information must accompany supply of an active ingredient—an important traceability and consumer-safety measure, even though retail supply is prohibited. Section 21 addresses wholesale of active ingredients, reinforcing that wholesale activities must be conducted in a compliant manner consistent with licence conditions and quality/distribution expectations.
5) Records, defects, and recall notification (Division 3 of Part 4). Sections 22–25 create a compliance and accountability framework. Section 22 requires a duty to maintain records of manufacture. Section 23 requires records of receipt and supply. Section 24 requires records of defects. Section 25 requires notification to the Authority concerning recall. For practitioners, this is one of the most operationally important parts of the Regulations: it establishes that regulated parties must be able to trace active ingredients through the supply chain, identify defects, and respond quickly to safety or quality issues. In a dispute or enforcement context, the adequacy of records and the timeliness of recall notification can be decisive.
6) Duties specific to licensees, including responsibility and licence changes (Division 4 of Part 4). Sections 26–30 impose additional duties on licensed manufacturers, importers, and wholesalers. Section 29 introduces the concept of a “responsible person”, which is a common regulatory mechanism to ensure there is a named individual accountable for compliance. Section 30 addresses changes affecting licences, meaning that if the business structure, premises, key personnel, or other relevant circumstances change, the licensee must notify or obtain approval as required. This is particularly relevant for corporate transactions, outsourcing arrangements, and changes in manufacturing sites or import supply chains.
7) Certificates for export and quality standards (Part 5). Part 5 sets out a certification regime. Section 31 explains the application of this Part. Section 32 provides for certification of active ingredients intended for export. Sections 33 and 34 relate to certificates of manufacturing standard and distribution standard, respectively. These provisions support international trade by providing documentary assurance that active ingredients were manufactured and distributed according to recognised standards. For exporters and their counsel, the key is to ensure that the certificate content, supporting records, and sign-off processes align with the Regulations and any HSA requirements.
8) Enforcement and procedural matters (Part 6). Section 35 provides that enforcement officers may conduct routine inspections. Section 36 addresses the form and manner of applications and notices, which matters for compliance planning and for avoiding procedural defects. Section 37 contains saving and transitional provisions, which typically preserve rights and obligations during changes in law or amendments—important when advising on legacy stock, existing licences, or ongoing compliance programmes.
How Is This Legislation Structured?
The Regulations are organised into seven main components. Part 1 (Preliminary) contains the citation/commencement and definitions, including technical terms and cross-references to other subsidiary legislation. Part 2 establishes prohibitions against manufacturing or dealing with adulterated, counterfeit, or unwholesome active ingredients. Part 3 creates the licensing regime, with Division 1 identifying when licences are required and Division 2 setting out licence issuance requirements. Part 4 imposes operational and compliance duties across storage/transport, import/export/supply, records/recall, and additional duties for licensees (including a responsible person and licence-change obligations). Part 5 provides for certificates, particularly for export. Part 6 covers enforcement powers and procedural provisions. The Schedule lists the “regulated active ingredients” to which the Regulations apply.
Who Does This Legislation Apply To?
The Regulations apply to persons who manufacture, import, or wholesale regulated active ingredients listed in the Schedule, as well as to other persons who may be captured by specific duties (for example, duties relating to supply information, recordkeeping, and recall). In most cases, the licensing provisions determine whether a party must hold a manufacturer’s, importer’s, or wholesaler’s licence.
However, the Regulations also apply indirectly through operational duties. Even where a party is exempt from a particular licence category under sections 9–11, it may still be subject to certain general duties depending on how the activity is characterised. For advice, practitioners should map the client’s exact activities (including logistics, warehousing, repackaging/label-labelling steps, and distribution channels) against the definitions of “manufacture” and “wholesale”, and against the Schedule listing.
Why Is This Legislation Important?
For legal and compliance practitioners, the Regulations are important because they operationalise quality and integrity controls for active ingredients—an upstream component that can determine the safety and efficacy of downstream health products. The prohibitions in Part 2 create clear enforcement hooks against counterfeit and adulterated products, while the licensing regime in Part 3 ensures that only capable and supervised entities participate in the regulated supply chain.
The recordkeeping and recall provisions in Part 4 (ss 22–25) are particularly significant. They require traceability and defect documentation, and they impose a duty to notify the Authority concerning recall. This directly affects how companies design their quality management systems, complaint handling, deviation investigations, and product withdrawal/recall workflows. In enforcement proceedings or civil litigation, the existence and quality of these records can be central to assessing compliance and liability.
Finally, the export certification provisions in Part 5 support cross-border trade while maintaining Singapore’s regulatory standards. Businesses exporting regulated active ingredients must ensure that their manufacturing and distribution practices align with the standards referenced in the Regulations and that certificate processes are robust and auditable.
Related Legislation
- Health Products Act 2007
- Pharmacists Registration Act 2007
- Health Products (Therapeutic Products) Regulations 2016 (for “psychotropic substance” definition)
- Health Products (Clinical Research Materials) Regulations 2016 (for “clinical research” definition)
- Health Products (Medical Devices) Regulations 2010 (for “laboratory-developed test” definition)
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (for “minimal manipulation” definition)
- Health Products (Licensing of Retail Pharmacies) Regulations 2016 (for “pharmacy licence” definition)
Source Documents
This article provides an overview of the Health Products (Active Ingredients) Regulations 2023 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.